Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With Taxotere

Vukelja, S.; Baker, William J.; Burris, Howard A.; Keeling, James H.; Hoff, D. Von

doi:10.1093/jnci/85.17.1432

Cited by 66 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Historically, pyridoxine was first used because of the resemblance of traditional HFS to acrodynia in pyridoxil-phosphate-depleted rodents, as well as the observation that several chemotherapeutic agents may hamper pyridoxine function [70,80]. Case reports and series dating back to 1989 have attested to the benefit of pyridoxine in doses of 50–300 mg daily for HFS from a variety of drugs [60,99,100]. Fabian et al [70] noted in 1990 that HFS resembled acrodynia from vitamin B 6 deficiency in rats, and analyzed data from 11 patients with HFS from their first exposure to 5-FU.…”

Section: Managementmentioning

confidence: 99%

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth¹,

2009

View full text Add to dashboard Cite

Hand-foot syndrome (HFS), also called hand-foot skin reaction, palmar-plantar erythrodysesthesia, acral erythema, and Burgdorf reaction, is a dose-limiting cutaneous toxicity of many chemotherapeutic agents. Recently, the multiple tyrosine kinase inhibitor class of novel targeted therapies, including sorafenib and sunitinib, has emerged as an important cause of HFS, with 10–28% of patients treated with sunitinib and 10–62% of patients treated with sorafenib reporting HFS. This review examines the epidemiology, clinical features, histopathology, pathogenesis models, prognostic implications, and management of HFS, with particular attention to HFS induced by sorafenib and sunitinib. The high prevalence of HFS reported by patients treated with these medications underscores the need for greater understanding of the pathogenesis and management of this syndrome.

show abstract

Section: Managementmentioning

confidence: 99%

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth¹,

2009

View full text Add to dashboard Cite

show abstract

“…Since HFS was found to resemble a rat disease (acrodynia) caused by pyridoxine deficiency, capecitabine-induced HFS was empirically treated with pyridoxine. Animal studies, case reports and other small studies previously suggested that the administration of pyridoxine may help prevent and treat HFS induced by chemotherapy drugs (9,10,(25)(26)(27)). It appears to be effective in preventing against HFS in at least some individuals who experience this side effect.…”

Section: B Amentioning

confidence: 97%

“…Since HFS was found to resemble a rat disease (acrodynia) caused by pyridoxine (vitamin B6) deficiency, capecitabine-associated HFS was empirically treated with pyridoxine (9,10). Several studies investigated whether pyridoxine is able to reduce the incidence of capecitabine-induced HFS (15,16,(30)(31)(32).…”

Section: Introductionmentioning

confidence: 99%

Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis

Zhou

Peng

et al. 2013

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Hand-foot syndrome (HFS) is a dose-limiting adverse event of capecitabine, which commonly leads to early discontinuation of capecitabine-based therapy in the palliative and adjuvant settings. Although pyridoxine has been used for the prevention of capecitabine-associated HFS, its efficacy is controversial. The aim of this study was to evaluate whether prophylactic pyridoxine reduces the incidence of capecitabine-associated HFS by performing a meta-analysis of the literature involving available studies. Systematic searches for trials were undertaken through PubMed, Embase, Web of Science, the Cochrane Library, the American Society of Clinical Oncology (ASCO) and the ASCO Gastrointestinal Cancers Symposium, updated to March, 2013, to identify relevant studies. A meta-analysis was conducted with eligible studies that evaluated the efficacy of the prophylactic use of pyridoxine against capecitabine-induced HFS. We performed a meta-analysis of five studies (n=793 patients) that evaluated the efficacy of the prophylactic use of pyridoxine in cancer patients treated with capecitabine. The odds ratio (OR) comparing prophylactic pyridoxine to placebo was 0.91 [95% confidence interval (CI): 0.67-1.24] for HFS of all grades; OR=1.17 (95% CI: 0.82-1.67) for HFS ≥ grade 2 and OR=1.05 (95% CI: 0.60-1.85) for HFS ≥ grade 3. Based on our meta-analysis, prophylactic pyridoxine did not appear to reduce the incidence of HFS in patients receiving capecitabine.

show abstract

“…Based on the observation that the clinical features of PPES are similar to those of acrodynia in pyridoxine-depleted animals (16), pyridoxine has been investigated as a tool for PPES therapy and prevention. Given orally in a dose ranging from 50 to 150 mg/day, pyridoxine turns out to be a treatment modality that frequently improves the symptoms of PPES, thus allowing continuation of 5-FU administration without any dose reduction (7,12). Furthermore, it has been shown that pyridoxine does not interfere with 5-FU antitumour activity (12).…”

Section: Acta Oncologica 36 (1997)mentioning

confidence: 99%

“…PPES tends to resolve a few days after 5-FU discontinuation but frequently recurs when therapy is reinstituted; oral administration of pyridoxine has been recommended as a treatment that allows continuation of chemotherapy with 5-FU while maintaining remission of this cutaneous complication (7). Most reports in the literature have linked PPES to long-term continuous infusion of 5-FU, and indeed PPES is presently recognized as a limiting toxicity of this treatment modality.…”

mentioning

confidence: 99%

Palmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapy–An Underestimated Toxic Event?

et al. 1997

View full text Add to dashboard Cite

Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With Taxotere

Cited by 66 publications

References 0 publications

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis

Palmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapy–An Underestimated Toxic Event?

Contact Info

Product

Resources

About